Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDER phase II study of tremelimumab + durvalumab + regorafenib in first-line advanced hepatocellular carcinoma
KCT0012755Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Dec 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab, durvalumab and regorafenib in hepatocellular carcinoma (HCC), sponsored by Boryung. Primary endpoint: Progression-free survival. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
tremelimumabdurvalumabregorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0012755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012755.